These drugs, which are among the most common types of blood thinners, can interfere with traditional coagulation tests, producing unreliable results.

The acquisition, which enables Qiagen to enter the single-cell sequencing market, is expected to close in December and contribute $40 million to 2026 revenues.

The French in vitro diagnostics company slightly lowered its full-year revenue guidance to adjust for a late respiratory infection season.

The next-generation sequencing-based test is designed to capture all clinically relevant cystic fibrosis mutations in a single assay.

Last week, readers were most interested in a story about Biodesix's journey as a publicly traded company and what lies ahead for it.

As a result of the firm's financial results, Castle Bio raised its full-year 2025 revenue guidance to between $327 and $335 million from a range of $310 to $320 million.

Of the 30 companies in the index, 21 firms saw their share prices rise month over month, while nine saw their stock prices decline.

The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in ...

NEW YORK — Tosoh Bioscience said on Thursday that it has received 510(k) clearance from the US Food and Drug Administration for its automated HLC-723 GR01 glycohemoglobin A1c (HbA1c) analyzer. The ...

The Dublin-based firm is developing an array of artificial intelligence-derived tools to improve the efficiency of its digital pathology outsourcing service.

Medicare Part B data show that of the 20 CPT codes seeing the largest increase in payments from 2022 to 2024, all are for molecular- or sequencing-based tests.